Thetis Pharmaceuticals

Thetis Pharmaceuticals is a biopharmaceutical company founded in 2011 and headquartered in the United States. The company's slogan, "Thetis is developing novel therapies that resolve inflammation without compromising immune function," encapsulates its core mission. Thetis is focused on developing first-in-class Resolvin therapies for the treatment of cancer and autoimmune diseases. These Resolvins are unique endogenous molecules that play a key role in regulating immune homeostasis. The latest investment secured by Thetis Pharmaceuticals amounted to $4.20M, in the form of a grant investment on 05 April 2022. This funding was provided by The Leona M. and Harry B. Helmsley Charitable Trust, showcasing the confidence that leading organizations have in Thetis's innovative approach to addressing inflammation and immune function. Thetis Pharmaceuticals operates within the Biotechnology and Pharmaceutical industries, where its groundbreaking work in developing therapies for cancer and autoimmune diseases holds significant promise. With its focus on resolving inflammation while maintaining immune function, Thetis is poised to make a meaningful impact in improving treatment options for these challenging medical conditions.